Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
Discontinued
Reference number: GID-TA10494
Following on from information provided to NICE by the company in April 2020 the appraisal of Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.